Previous Year Event Recaps

2023 Agenda

7:15 am Sign-In, Continental Breakfast, Poster Set-Up    
8:00 am  

Welcome/Purpose of Symposium

 
Susan F. Smith Center Leaders
8:10 am

M. PATRICIA CRONIN MEMORIAL LECTURE
“STICs make tumors nervous”
Ronny Drapkin, M.D., Ph.D.
Franklin Payne Chair in Gynecologic Oncology
Director, Penn Ovarian Cancer Research Center
Director, Gynecologic Cancer Research, Basser Center for BRCA
Assistant Dean, Department of Defense Ovarian Cancer Academy
(35-40 min talk, 10 mins questions)

9:00 am 

SESSION I: Genomics
Chair: Gerburg Wulf

9:00 – 9:45 am

3 oral presentations (12 mins each); 3 mins questions

Abstract #25

Dominik Glodzik: Timing onset of homologous recombination deficiency before cancer diagnosis in BRCA1/2 mutation carriers

Abstract #26

Po-Han Lin: Genomics and transcriptomics landscape of early pathogenesis of the BRCA1/2-associated breast cancer

Abstract #27

Stefania Morganti: Clonal hematopoiesis of indeterminate potential (CHIP) after (neo)adjuvant chemotherapy (CT) versus endocrine therapy (ET) for early breast cancer (eBC): the CIRCE-eBC prospective cohort study

9:45 am

POSTER SESSION
9:45 am – 10:30 am – Open Posters

10:30 am 

SESSION II: Risk, Prevention & Disparities/Clinical

 
Chair: Sara Tolaney
10:30 – 11:30 am4 oral presentations (12 mins each); 3 mins questions 
Abstract #5

Cheng Peng: Regular Aspirin Use and Long-term Breast Cancer Survival

Abstract #19Joseph Dottino: Who is first in line? Trends in use of poly-ADP ribose polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer
Abstract #22Filipa Lynce: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)
Abstract #31

MacLean Sellars: Personalized targeted circulating tumor DNA (ctDNA) to monitor response to combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer

11:30 am 

J. DIRK IGLEHART, M.D., VISITING SCHOLAR LECTURE
“Regulatory Strategies to Address Unmet Need in Breast Cancer”

Tatiana M. Prowell, M.D.
Breast Cancer Scientific Liaison, U.S. Food and Drug Administration
Associate Professor of Oncology, Breast Cancer Program, Johns Hopkins           
University School of Medicine
(35-40 min talk, 10 mins questions)

12:15 pm

Lunch and Open Posters
12:15 – 1:15pm

 1:15 pm 

SESSION III: Drug Resistance/Animal Models
Chair: Patricia Donahoe

1:15 – 2:15 pm4 oral presentations (12 mins each); 3 mins questions
Abstract #43Joshua Rivera: Single Cell Transcriptomics Reveals Putative Tumor Promoting Subpopulation in Brca1 Mutant Breast Cancer Mouse Model
Abstract #45

Alexandre da Costa: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance

Abstract #57 

Bogang Wu: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer

Abstract #59Oladapo Yeku: Antibody Drug Conjugates against MUC16 for Ovarian Cancer
2:15-2:30  15-Minute Break
2:30 pm  SESSION IV: Tumor Microenvironment/Immunology
Chair: Jean Zhao
2:30 – 3:30 pm

 4 oral presentations (12 mins each); 3 mins questions

Abstract #32

Triet Bui: The Single-Cell Trajectory of Immune Escape During DCIS-IDC Progression

Abstract #34 Maeva Chauvin: The role of cancer-associated mesothelial cells in the ovarian tumor microenvironment
Abstract #35

Jenny Hogstrom: Modeling drug resistance in ER+ breast cancer using patient-derived organoid cultures and cancer-associated fibroblasts

Abstract #62

Jeffrey Patterson-Fortin: Polymerase θ inhibition activates the cGAS-STING pathway in BRCA1-deficient breast cancer

3:30 pm

Announcement of Awards and Adjourn

Hide

2020 Agenda

Please note: This event was canceled in 2020 due to Covid


7:15 amSign-In, Continental Breakfast, Poster Set-Up
8:00 am

Welcome/Purpose of Symposium
Susan F. Smith Center Leaders

8:10 am

M. Patricia Cronin Memorial Lecture
“Nervous Tumors: Cancer-derived vesicles promote nerve recruitment and treatment resistance in ovarian cancer”

Ronny Drapkin, MD, PhD
The Franklin Payne Associate Professor of Pathology
Director, Penn Ovarian Cancer Research Center; Director, Gynecologic Cancer Research, Basser Center for BRCA; Director, Abramson Translation Center of Excellence in Ovarian Cancer, University of Pennsylvania

9:00 amSESSION I: Genomics

Chair: Gerburg Wulf

  • Arthur Lambert:p63/p73 are transcriptional drivers of cancer stem cells residing in an intermediate EMT state
  • Rebecca Porter:Repeatome profiling identifies novel molecular biomarkers and therapeutic targets in epithelial ovarian cancer
  • Nobuhiro Takahashi:A Personalized Approach to Identify and Target Ovarian Cancer Liabilities
9:45 amPoster Session
10:30 am

SESSION II: Risk/Prevention/Clinical
Chair: Sara Tolaney

  • Tengteng Wang:Post-diagnosis diabetes risk reduction diet and survival following breast cancer
  • Tanya Keenan:A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC)
  • Jan Heng:Tobacco use, alcohol consumption, and breast cancer somatic genomic alterations
11:15 am

J. Dirk Iglehart, MD Visiting Scholar Lecture
Regulatory Strategies to Address Unmet Need in Breast Cancer”

Tatiana M. Prowell, MD
Breast Cancer Scientific Liaison, U.S. Food and Drug Administration
Associate Professor of Oncology, Breast Cancer Program, Johns Hopkins University School of Medicine

12:00 pmLunch and Open Posters
1:00 pm

SESSION III: Drug Resistance/Animal Models
Chair: Patricia Donahoe

  • Masa Aleckovic:Mammary tumor prevention by inhibition of TGF-beta signaling
  • Akshaya Chandrasekaran:PAX8-directed nanotherapeutics for high-grade serous ovarian cancer
  • Jia Zhou:Polymerase Theta Inhibition Overcomes PARP Inhibitor Resistance
1:45 pm

SESSION IV: Tumor Biology/Immunology
Chair: Jean Zhao

  • Johann Bergholz:Potentiating immunotherapy in PTEN-deficient triple-negative breast cancer by isoform-specific PI3Kβ inhibition
  • Yihao Li:Enhancer activation mediates resistance to FGFR inhibitors in triple-negative breast cancer
  • Francisco Hermida-Prado:Role of the estrogen receptor axis in the modulation of the immune response in ER+ Breast Cancers
2:30 pmAnnouncements of Awards and Adjourn
Hide

2019 Agenda

7:15 am Sign-In, Continental Breakfast, Poster Set-Up
8:00 am 

Welcome/Purpose of Symposium
Susan F. Smith Center Leaders

8:10 am 

M. Patricia Cronin Memorial Lecture
“Loss of Base Excision Repair Drives Drug Resistance in BRCA2 Mutant Ovarian Cancer"
Shailja Pathania, Ph.D.

Assistant Professor, Center for Personalized Cancer Therapy
University of Massachusetts Boston
 9:00 am SESSION I: Genomics

Chair: Gerburg Wulf

  • Rajula Elango: Coordination of stalled replication fork repair by Fanconi anemia gene product Slx4
  • Doga Gulhan: Detecting the mutational signature of homologous recombination deficiency in clinical samples
  • Mihriban Karaayvaz: Aneuploidy and suppressed DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers
 9:45 amPoster Session 
10:30 am 

SESSION II: Risk/Prevention/Clinical
Chair: Rulla Tamimi

  • Emma McGee: Plasma osteoprotegerin and breast cancer risk: A nested case-control study within the Nurses’ Health Study II
  • Oana Zeleznik: Mammogram-derived texture features and risk of breast cancer
  • Hanneke Poort: Predictors and Trajectories of Fatigue in Ovarian and Uterine Cancer
11:15 am 

J. Dirk Iglehart, MD Visiting Scholar Lecture
“Unraveling the drivers of breast cancer: phenotypic plasticity meets mutations in long-tail genes”
Charlotte Kuperwasser, PhD
Director, Raymond and Beverly Sackler Convergence Laboratory (RBSCL)
Professor Developmental, Molecular & Chemical Biology
Tufts University School of Medicine 
(35-40 min talk, 10 mins questions)

12:00 pm Lunch and Open Posters 
1:00 pm 

SESSION III: Drug Resistance/Animal Models
Chair: Patricia Donahoe

  • Carlos Gil del Alcazar: Immune related strategies for prevention of breast tumor initiation and progression
  • Akshaya Chandrasekaran: PAX8-directed nanotherapeutics for high grade serous ovarian cancer
  • Prabha Sarangi: The TRIP13 ATPase mediates PARP inhibitor resistance by promoting homologous recombination 
1:45 pm 

SESSION IV: Tumor Biology/Immunology
Chair: Jean Zhao 

  • Kirsten Kubler: Tamoxifen-associated uterine corpus cancer is characterized by the lack of mutational activation in the PI3K-AKT-mTOR pathway
  • Sonia Iyer: Novel Syngeneic Mouse Models of High-Grade Serous Ovarian Carcinoma reveal distinct tumor microenvironments for Homologous Recombination -Deficient and -Proficient tumors
  • Jennifer Guerriero: Harnessing Macrophages in Triple Negative Breast Cancer (TNBC) to Overcome PARP Inhibitor Resistance
2:30 pm  Announcements of Awards and Adjourn
Hide

2018 Agenda

7:15 am Sign-In, Continental Breakfast, Poster Set-Up
8:00 am 

Welcome/Purpose of Symposium
Alan D’Andrea, M.D. - Ursula Matulonis, M.D. - Eric Winer, M.D.

8:10 am 

KATHRYN FOX SAMWAY MEMORIAL LECTURE:
“Mechanisms that maintain genome stability”
Andre Nussenzweig, Ph.D.
NIH Distinguished Investigator, Laboratory of Genome Integrity
National Cancer Institute, Center for Cancer Research

 9:00 am SESSION I: Genomics

Chair: Gerburg Wulf

  • Hui Liu: Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer
  • Johnathan R. Whetstine: Balancing Lysine Methylation Impacts Site-Specific DNA Copy Gains Associated with Aggressive Disease
  • Nicholas A. Willis: BRCA1 suppresses genomic instability specific to defects in stalled fork repair in mammalian cells
 9:45 amPoster Session 
10:30 am 

SESSION II: Clinical/Translational
Chair: Patricia Donahoe

  • Adrienne G. Waks: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab
  • Anniina Färkkilä: DNA damage- and immune profiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer
  • Golnaz Morad: Using proteomics profiling to elucidate the interactions of breast cancer-derived exosomes with the blood brain barrier
11:15 am 

M. PATRICIA CRONIN MEMORIAL LECTURE:
“Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy”
Kunle Odunsi, M.D., Ph.D.
Cancer Center Deputy Director, The M. Steven Piver Professor and Chair, Department of Gynecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center

12:00 pm Lunch and Open Posters 
12:45 pm 

SESSION III: Risk/Prevention 
Chair: Rulla Tamimi 

  • Cheng Peng: Transcriptomic network analysis reveals molecular mechanisms linking radon exposure to breast cancer etiology in breast tumor and tumor-adjacent tissues
  • Claire H. Kim: Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression in the Nurses’ Health Study II
  • Motohiro Kano: Concurrent MIS/AMH treatment during chemotherapy preserves the ovarian reserve and fertility
1:30 pm 

SESSION IV: Tumor Biology
Chair: Jean Zhao 

  • Johann Bergholz: PI3Kβ mediates immune evasion in PTEN-deficient triple-negative breast cancer
  • Constantia Pantelidou: The covalent CDK12 Inhibitor MFH290 has monotherapy activity in homologous recombination repair-deficient breast and ovarian cancer models and reverses PARP inhibitor resistance
  • Sarah J. Hill: Rapid assessment of DNA repair inhibitors and checkpoint blockade efficacy in short term patient-derived ovarian cancer organoids
2:15 pm Special Seminar:

“Targeting Galectin 3 Action for Tumor Growth Suppression and Metastasis”

David Spriggs, M.D.
2:30 pm  Annoucements of Awards and Adjourn
Hide